Overview

* Jaguar Health ( JAGX ) Q3 net revenue flat year-over-year

* Company reports Q3 net loss of $9.5 mln, a slight improvement from last year

Result Drivers

* R&D EXPENSES - Decrease due to conclusion of Phase 3 OnTarget clinical trial

* G&A expense increased by approximately $0.3 million, from $3.8 million for the quarter ended September 30, 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $3.08

Revenue mln

Q3 Net -$9.5

Income mln

Q3 -$8.88

Adjusted mln

EBITDA

Q3 Basic -$6.28

EPS

Q3 -$7.24

Operatin mln

g Income

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the pharmaceuticals peer group is "buy."

* Wall Street's median 12-month price target for Jaguar Health Inc ( JAGX ) is $16.00, about 88.9% above its November 14 closing price of $1.78

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)